Navigation Links
Sigma-Aldrich Names Patrick Sullivan New VP of Research and Development for Research Biotech
Date:9/27/2007

ST. LOUIS, Sept. 27 /PRNewswire-FirstCall/ -- Sigma-Aldrich (Nasdaq: SIAL) is pleased to announce that Patrick M. Sullivan has been named the Vice President of R&D for the Research Biotech business unit, effective October 1, 2007. In this role, he will help expand Sigma-Aldrich's leadership position through the development of new and innovative products for life science researchers. Sullivan has been involved with Sigma-Aldrich since 2005 as a member of the Company's Scientific Advisory Board, where he provided a large pharmaceutical perspective on new strategic plans and product offerings in the Company's Research Biotech business unit. Sullivan will report directly to David A. Smoller, Ph.D., President of Research Biotech.

Pat Sullivan has over 19 years of experience using and developing genomic-based solutions for the pharmaceutical and biotech industries. He was employed by Monsanto/Searle/Pharmacia for 12 years, where he provided molecular biology support for Inflammation and angiogenesis new target/biomarker discovery projects. He joined Incyte Genomics in 2000 as the Vice President of Global Operations, responsible for managing all genomic products and services. Most recently, Sullivan was employed by Pfizer, where he led efforts to identify new therapeutic opportunities in osteoarthritis and cardiovascular diseases.

"We are pleased to have such an strong and experienced leader join our organization," said David A. Smoller. "Patrick's combination of technical expertise, strong ability to analyze complex business operations and implement strategies to improve performance will be an immediate asset to our Research Biotech business unit's mission of bringing innovative technologies and solutions to life science researchers. We look forward to having him join us in making these valuable contributions to our life science community."

Sullivan received his B.S. degree in Microbiology from Western Illinois University and his M.S. degree in Molecular Biology from Southern Illinois University.

About Sigma-Aldrich: Sigma-Aldrich is a leading Life Science and High Technology company. Its biochemical and organic chemical products and kits are used in scientific and genomic research, biotechnology, pharmaceutical development, the diagnosis of disease and as key components in pharmaceutical and other high technology manufacturing. The Company has customers in life science companies, university and government institutions, hospitals, and industry. Over one million scientists and technologists use its products. Sigma-Aldrich operates in 36 countries and has 7,700 employees providing excellent service worldwide. Sigma-Aldrich is committed to Accelerating Customer Success through Leadership in Life Science, High Technology and Service. For more information about Sigma-Aldrich, please visit its award-winning Web site at sigma-aldrich.com.

Cautionary Statement: This release contains forward-looking statements relating to future performance, goals, strategic actions and initiatives and similar intentions and beliefs and other statements regarding the Company's expectations, goals, beliefs, intentions and the like, which involve assumptions regarding the Company's operations and conditions in the markets the Company serves. The Company does not undertake any obligation to update these forward-looking statements.


'/>"/>
SOURCE Sigma-Aldrich
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Wisconsin IT association names Gee president, CEO
2. Quintessence Biosciences names new president
3. CDW names VP to handle Berbee merger
4. NimbleGen names CFO with capital-raising past
5. Cisco names Berbee a top partner of 2005
6. Cisco names Inacom most innovative partner
7. UW-Madison medical school names new dean
8. GE Healthcare names new CEO
9. Bruker AXS names new leadership
10. Sonic Foundry names new senior vice president
11. MyWeather names new president, marketing officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... and PETACH TIKVAH, ... -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a ... for neurodegenerative diseases, announced financial results for ... "2016 was a highly successful and ... achievements and significant progress made on clinical, ...
(Date:3/29/2017)... , March 29, 2017  Halozyme Therapeutics, Inc. ... and drug-delivery therapies, today announced that an Oncologic ... Drug Administration voted 11 to 0 that the ... injection was favorable for patients in the proposed ... and chronic lymphocytic leukemia. The FDA action date ...
(Date:3/29/2017)... CT (PRWEB) , ... March 29, 2017 , ... Bactana ... and hormones in the world’s food supply through enhancement of the gut microbiota, today ... round included Connecticut Innovations , New York-based Sustainable Income Capital Management, LLC and ...
(Date:3/29/2017)... March 29, 2017 /PRNewswire/ -  GeneNews Limited (TSX:GEN) ("GeneNews" ... , a new risk stratification test for breast cancer, via ... Diagnostics Laboratory ("IDL"). BreastSentry incorporates a blood-based biomarker test with ... risk for developing breast cancer.   ... BreastSentry measures the fasting plasma ...
Breaking Biology Technology:
(Date:2/21/2017)... and PORTLAND, Ore. , Feb. 22, ... Avamere Family of Companies (Avamere Health Services, Infinity Rehab, ... six-month research study that will apply the power of ... senior living and health centers. By analyzing data streaming ... gain insights into physical and environmental conditions, and obtain ...
(Date:2/14/2017)... 2017  Wake Forest Baptist Medical Center today announced Julie ... executive officer (CEO). Freischlag joins the medical center on ... , M.D., who last year announced that he would ... after leading it since 2008.   As ... Forest Baptist,s academic health system, which includes Wake Forest ...
(Date:2/10/2017)... 2017 Research and Markets has ... Medicine - Scientific and Commercial Aspects" to their offering. ... ... integrated with therapy for selection of treatment as well for ... prevention of disease in modern medicine. Biochip/microarray technologies and next ...
Breaking Biology News(10 mins):